Korea United Pharm Inc. (033270.KS)
KRW 18480.0
(-1.75%)
KRW 18480.0
(-1.75%)
| Year | Revenue | Revenue Growth |
|---|---|---|
| 2023 | 278.94 Billion KRW | 6.26% |
| 2022 | 262.52 Billion KRW | 18.77% |
| 2021 | 221.03 Billion KRW | 2.36% |
| 2020 | 215.94 Billion KRW | -2.42% |
| 2019 | 221.31 Billion KRW | 4.42% |
| 2018 | 211.93 Billion KRW | 7.57% |
| 2017 | 197.02 Billion KRW | 11.37% |
| 2016 | 176.9 Billion KRW | 9.17% |
| 2015 | 162.04 Billion KRW | 4.42% |
| 2014 | 155.18 Billion KRW | 13.37% |
| 2013 | 136.89 Billion KRW | 1.53% |
| 2012 | 134.82 Billion KRW | -7.3% |
| 2011 | 145.45 Billion KRW | 7.78% |
| 2010 | 134.95 Billion KRW | 13.33% |
| 2009 | 119.08 Billion KRW | 25.75% |
| 2008 | 94.7 Billion KRW | 58.64% |
| 2007 | 59.69 Billion KRW | -11.68% |
| 2006 | 67.59 Billion KRW | 0.0% |
| Year | Revenue | Revenue Growth |
|---|---|---|
| 2024 Q3 | 71.35 Billion KRW | 0.51% |
| 2024 Q1 | 73.17 Billion KRW | 3.07% |
| 2024 Q2 | 70.99 Billion KRW | -2.98% |
| 2023 Q4 | 70.99 Billion KRW | 0.54% |
| 2023 Q3 | 70.61 Billion KRW | 3.03% |
| 2023 Q2 | 68.53 Billion KRW | -0.38% |
| 2023 Q1 | 68.79 Billion KRW | -0.09% |
| 2023 FY | 278.94 Billion KRW | 6.26% |
| 2022 FY | 262.52 Billion KRW | 18.77% |
| 2022 Q3 | 65.75 Billion KRW | 2.24% |
| 2022 Q1 | 63.59 Billion KRW | 12.33% |
| 2022 Q2 | 64.31 Billion KRW | 1.14% |
| 2022 Q4 | 68.85 Billion KRW | 4.71% |
| 2021 Q3 | 57.13 Billion KRW | -0.09% |
| 2021 Q4 | 56.61 Billion KRW | -0.91% |
| 2021 Q1 | 50.11 Billion KRW | -12.04% |
| 2021 FY | 221.03 Billion KRW | 2.36% |
| 2021 Q2 | 57.18 Billion KRW | 14.11% |
| 2020 Q1 | 53.11 Billion KRW | -6.51% |
| 2020 Q2 | 50.89 Billion KRW | -4.17% |
| 2020 Q3 | 54.96 Billion KRW | 8.0% |
| 2020 Q4 | 56.97 Billion KRW | 3.65% |
| 2020 FY | 215.94 Billion KRW | -2.42% |
| 2019 Q1 | 55.31 Billion KRW | -5.45% |
| 2019 Q3 | 54.69 Billion KRW | 0.36% |
| 2019 FY | 221.31 Billion KRW | 4.42% |
| 2019 Q4 | 56.8 Billion KRW | 3.87% |
| 2019 Q2 | 54.49 Billion KRW | -1.47% |
| 2018 FY | 211.93 Billion KRW | 7.57% |
| 2018 Q4 | 58.49 Billion KRW | 14.86% |
| 2018 Q1 | 50.81 Billion KRW | 4.15% |
| 2018 Q2 | 51.7 Billion KRW | 1.75% |
| 2018 Q3 | 50.92 Billion KRW | -1.5% |
| 2017 Q1 | 47.14 Billion KRW | 2.08% |
| 2017 Q3 | 51.42 Billion KRW | 3.56% |
| 2017 Q2 | 49.66 Billion KRW | 5.34% |
| 2017 FY | 197.02 Billion KRW | 11.37% |
| 2017 Q4 | 48.78 Billion KRW | -5.14% |
| 2016 Q2 | 41.91 Billion KRW | -4.91% |
| 2016 Q4 | 46.18 Billion KRW | 3.26% |
| 2016 Q3 | 44.72 Billion KRW | 6.71% |
| 2016 FY | 176.9 Billion KRW | 9.17% |
| 2016 Q1 | 44.07 Billion KRW | 0.0% |
| 2015 FY | 162.04 Billion KRW | 4.42% |
| 2015 Q4 | - KRW | -100.0% |
| 2015 Q3 | 39.95 Billion KRW | 1.54% |
| 2015 Q2 | 39.34 Billion KRW | -3.6% |
| 2015 Q1 | 40.81 Billion KRW | -1.22% |
| 2014 Q4 | 41.32 Billion KRW | 9.73% |
| 2014 FY | 155.18 Billion KRW | 13.37% |
| 2014 Q1 | 38.26 Billion KRW | 7.45% |
| 2014 Q3 | 37.65 Billion KRW | -0.78% |
| 2014 Q2 | 37.95 Billion KRW | -0.81% |
| 2013 Q4 | 35.6 Billion KRW | 12.17% |
| 2013 FY | 136.89 Billion KRW | 1.53% |
| 2013 Q1 | 33.23 Billion KRW | 5.27% |
| 2013 Q2 | 36.3 Billion KRW | 9.22% |
| 2013 Q3 | 31.74 Billion KRW | -12.55% |
| 2012 Q3 | 33.01 Billion KRW | -6.29% |
| 2012 Q4 | 31.57 Billion KRW | -4.37% |
| 2012 FY | 134.82 Billion KRW | -7.3% |
| 2012 Q1 | 35.01 Billion KRW | 0.0% |
| 2012 Q2 | 35.22 Billion KRW | 0.61% |
| 2011 Q3 | 35.78 Billion KRW | -3.38% |
| 2011 Q2 | 37.03 Billion KRW | 6.11% |
| 2011 FY | 145.45 Billion KRW | 7.78% |
| 2011 Q1 | 34.89 Billion KRW | -4.58% |
| 2011 Q4 | - KRW | -100.0% |
| 2010 Q2 | 34.39 Billion KRW | 12.38% |
| 2010 Q1 | 30.6 Billion KRW | -1.3% |
| 2010 Q4 | 36.57 Billion KRW | 9.53% |
| 2010 Q3 | 33.39 Billion KRW | -2.91% |
| 2010 FY | 134.95 Billion KRW | 13.33% |
| 2009 Q4 | 31 Billion KRW | 5.78% |
| 2009 FY | 119.08 Billion KRW | 25.75% |
| 2009 Q1 | 26.67 Billion KRW | 3.41% |
| 2009 Q2 | 32.08 Billion KRW | 20.29% |
| 2009 Q3 | 29.31 Billion KRW | -8.66% |
| 2008 Q4 | 25.79 Billion KRW | 12.48% |
| 2008 Q2 | 22.92 Billion KRW | -0.5% |
| 2008 Q1 | 23.04 Billion KRW | 0.0% |
| 2008 FY | 94.7 Billion KRW | 58.64% |
| 2008 Q3 | 22.93 Billion KRW | 0.05% |
| 2007 Q2 | 19.05 Billion KRW | 0.0% |
| 2007 Q3 | 18.8 Billion KRW | -1.35% |
| 2007 FY | 59.69 Billion KRW | -11.68% |
| 2006 FY | 67.59 Billion KRW | 0.0% |
| Name | Revenue | Revenue Difference |
|---|---|---|
| Yuyu Pharma, Inc. | 137.2 Billion KRW | -103.297% |
| Dong-A Socio Holdings Co., Ltd. | 1132 Billion KRW | 75.358% |
| Ildong Holdings Co., Ltd. | 638.44 Billion KRW | 56.309% |
| HANDOK Inc. | 522.74 Billion KRW | 46.638% |
| Kukje Pharma Co., Ltd. | 135.37 Billion KRW | -106.056% |
| Yuhan Corporation | 1858.98 Billion KRW | 84.995% |
| Dong-A ST Co., Ltd. | 663.98 Billion KRW | 57.989% |
| SAMSUNG PHARM. Co., LTD. | 51.95 Billion KRW | -436.894% |
| Hanmi Pharm. Co., Ltd. | 1490.88 Billion KRW | 81.29% |
| Hanall Biopharma Co.,Ltd | 134.9 Billion KRW | -106.763% |
| Ilyang Pharmaceutical Co.,Ltd | 370.53 Billion KRW | 24.719% |
| Dong Sung Bio Pharm.Co.,Ltd. | 88.59 Billion KRW | -214.857% |
| MYUNGMOON Pharm co.,Ltd | 169.56 Billion KRW | -64.503% |
| Hana Pharm Co., Ltd. | 224.45 Billion KRW | -24.275% |
| Yuyu Pharma, Inc. | 137.2 Billion KRW | -103.297% |
| Ilsung Pharmaceuticals Co., Ltd. | 78.05 Billion KRW | -257.376% |
| REYON Pharmaceutical Co., Ltd. | 151.07 Billion KRW | -84.644% |
| Aprogen pharmaceuticals,Inc. | 87.36 Billion KRW | -219.29% |
| JW Holdings Corporation | 928.07 Billion KRW | 69.944% |
| Ildong Pharmaceutical Co., Ltd. | 600.75 Billion KRW | 53.568% |
| Chong Kun Dang Pharmaceutical Corp. | 1669.4 Billion KRW | 83.291% |
| JW Pharmaceutical Corporation | 748.52 Billion KRW | 62.734% |
| Shin Poong Pharm.Co.,Ltd. | 200.22 Billion KRW | -39.312% |
| Hyundai Pharmaceutical Co., Ltd. | 180.76 Billion KRW | -54.315% |
| Samil Pharmaceutical Co.,Ltd | 196.34 Billion KRW | -42.067% |
| Jeil Pharmaceutical Co.,Ltd | 726.39 Billion KRW | 61.599% |
| Yuyu Pharma, Inc. | 137.2 Billion KRW | -103.297% |
| Kwang Dong Pharmaceutical Co., Ltd. | 1514.45 Billion KRW | 81.581% |
| Daewoong pharmaceutical Co.,Ltd | 1375.32 Billion KRW | 79.718% |
| JW Pharmaceutical Corporation | 748.52 Billion KRW | 62.734% |
| Yuhan Corporation | 1858.98 Billion KRW | 84.995% |
| Jeil Pharma Holdings Inc | 794.71 Billion KRW | 64.9% |
| Yungjin Pharm. Co., Ltd. | 234.9 Billion KRW | -18.749% |
| Suheung Co., Ltd. | 594.56 Billion KRW | 53.085% |
| JW Pharmaceutical Corporation | 748.52 Billion KRW | 62.734% |
| Samjin Pharmaceuticals Co., Ltd. | 292.12 Billion KRW | 4.514% |
| CKD Bio Corp. | 160.35 Billion KRW | -73.956% |
| Daewon Pharmaceutical Co., Ltd. | 526.95 Billion KRW | 47.065% |
| Dongwha Pharm.Co.,Ltd | 361.1 Billion KRW | 22.754% |
| Whan In Pharm Co.,Ltd. | 230.39 Billion KRW | -21.073% |
| Shin Poong Pharm.Co.,Ltd. | 200.22 Billion KRW | -39.312% |
| Chong Kun Dang Holdings Corp. | 879.78 Billion KRW | 68.294% |
| Boryung Corporation | 859.62 Billion KRW | 67.551% |
| Bukwang Pharmaceutical Co., Ltd. | 125.92 Billion KRW | -121.51% |
| Ilyang Pharmaceutical Co.,Ltd | 370.53 Billion KRW | 24.719% |
| JW Lifescience Corporation | 206.86 Billion KRW | -34.846% |